Search Within

Solid Tumor Oncology Division

  1. "American Association for Cancer Research"
Formats
  1. Meeting Abstract (1150)
  2. Journal Article (1090)
  3. Editorial (48)
  4. Review (24)
  5. Miscellaneous (2)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (2316)
  2. GSK Faculty (1093)
  3. Breast Medicine Service (749)
  4. Genitourinary Oncology Service (688)
  5. Human Oncology and Pathogenesis Program (560)
  6. Sloan Kettering Institute Postdocs (510)

More Groups

People
  1. David Solit (218)
  2. Neal Rosen (211)
  3. Howard Scher (197)
  4. Clifford Hudis (163)
  5. Jedd Wolchok (130)
  6. Michael Berger (126)

More People

Years
  1. 2025 (22)
  2. 2024 (81)
  3. 2023 (72)
  4. 2022 (177)
  5. 2021 (181)
  6. 2020 (207)

More Years

Publications
  1. Cancer Research (1012)
  2. Clinical Cancer Research (768)
  3. Proceedings of the American Association for Cancer Research Annual Meeting (183)
  4. Cancer Discovery (157)
  5. Molecular Cancer Therapeutics (50)
  6. Cancer Epidemiology Biomarkers and Prevention (47)

More Publications

Publishers
  1. American Association for Cancer Research (2316)

Results (2316)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer
    Meeting Abstract

    Beckwith, H. C.; Medgyesy, D. C.; Abraham, J.; Nanda, R.; Tkaczuk, K. H. R.; Krop, I. E.; Pusztai, L.; Modi, S.; Mita, M. M.; Specht, J. M.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase I/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Meeting Abstract

    Bedard, P. L.; Jhaveri, K.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; Saura, C.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Secondary outcomes in a randomized controlled trial of acupuncture versus sham acupuncture and usual care in solid tumor survivors with chemotherapy-induced peripheral neuropathy
    Meeting Abstract

    Bao, T.; Baser, R.; Lin, C.; Li, Q.; Piulson, L.; Zhi, I.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
    Meeting Abstract

    Hurvitz, S.; Vahdat, L.; Harbeck, N.; Wolff, A. C.; Tolaney, S. M.; Loi, S.; Masuda, N.; O'Shaughnessy, J.; Dong, C.; Walker, L.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
    Meeting Abstract

    Rugo, H.; Llombart-Cussac, A.; Andre, F.; Robson, M. E.; Saji, S.; Harbeck, N.; Schmid, P.; Cescon, D.; Ahn, J. S.; Nanda, R.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase 1b/2 study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations
    Meeting Abstract

    Aftimos, P.; Oliveira, M.; Punie, K.; Boni, V.; Hamilton, E.; Gucalp, A.; Shah, P.; Mina, L.; Sharma, P.; Bauman, L.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Impact of online education regarding novel HER2 therapies on translating evidence to practice
    Meeting Abstract

    Parikh, K.; Dorkhom, N.; Chen, P.; Cameron, D. R.; Caraico, R.; Hanley, K.; Modi, S.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)
    Meeting Abstract

    Andre, F.; Hamilton, E.; Loi, S.; Schmid, P.; Yu, T.; Lu, S.; Boston, S.; D'Cruz, C.; Herbolsheimer, P.; Jhaveri, K.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Phase Ib/II trial of copanlisib in combination with trastuzumab and pertuzumab after induction treatment of HER2 positive metastatic breast cancer with PIK3CA mutation or PTEN mutation
    Meeting Abstract

    Damodaran, S.; Murthy, R. K.; Nusrat, M.; Saigal, B.; Trager, S. C.; Tripathy, D.; Meric-Bernstam, F.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • What are some different ways to evaluate immunotherapy combinations?
    Meeting Abstract

    Postow, M.
    Cancer Immunology Research (2021)

    Fulltext@MSK | Save